Repros Therapeutics Inc. (NASDAQ:RPRX) will be releasing its Q2 2017 earnings data before the market opens on Monday, August 14th. Analysts expect Repros Therapeutics to post earnings of ($0.22) per share for the quarter.
Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.08. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. The business had revenue of $0.01 million for the quarter. On average, analysts expect Repros Therapeutics to post $-1.07 EPS for the current fiscal year and $-1.01 EPS for the next fiscal year.
Repros Therapeutics Inc. (RPRX) opened at 0.35 on Friday. The company’s market cap is $9.36 million. Repros Therapeutics Inc. has a 52-week low of $0.29 and a 52-week high of $2.48. The stock’s 50 day moving average is $0.41 and its 200 day moving average is $0.83.
Separately, Laidlaw lowered Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.
About Repros Therapeutics
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
What are top analysts saying about Repros Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repros Therapeutics Inc. and related companies.